BR112018014215A2 - anticorpo de ligação ao psma e usos do mesmo - Google Patents
anticorpo de ligação ao psma e usos do mesmoInfo
- Publication number
- BR112018014215A2 BR112018014215A2 BR112018014215A BR112018014215A BR112018014215A2 BR 112018014215 A2 BR112018014215 A2 BR 112018014215A2 BR 112018014215 A BR112018014215 A BR 112018014215A BR 112018014215 A BR112018014215 A BR 112018014215A BR 112018014215 A2 BR112018014215 A2 BR 112018014215A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding antibody
- antibody
- psma
- psma binding
- pmsa
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção fornece um anticorpo de ligação ao psma denominado 10b3 e usos farmacêuticos e diagnósticos do anticorpo 10b3. o anticorpo anti-psma 10b3 não compete de forma cruzada com o anticorpo de ligação ao pmsa j591 do estado da técnica e tem uma indução reduzida de desvio antigênico comparado com o j591 e uma reatividade única com células de carcinoma de células escamosas (scc) de origem diferente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16151281.9A EP3192810A1 (en) | 2016-01-14 | 2016-01-14 | Psma binding antibody and uses thereof |
PCT/EP2017/050834 WO2017121905A1 (en) | 2016-01-14 | 2017-01-16 | Psma binding antibody and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018014215A2 true BR112018014215A2 (pt) | 2018-12-26 |
Family
ID=55349634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018014215A BR112018014215A2 (pt) | 2016-01-14 | 2017-01-16 | anticorpo de ligação ao psma e usos do mesmo |
Country Status (17)
Country | Link |
---|---|
US (2) | US11612646B2 (pt) |
EP (3) | EP3192810A1 (pt) |
JP (1) | JP6893939B2 (pt) |
CN (1) | CN108699157B (pt) |
AU (2) | AU2017207947B9 (pt) |
BR (1) | BR112018014215A2 (pt) |
CA (2) | CA3199697A1 (pt) |
DK (1) | DK3402821T3 (pt) |
ES (1) | ES2963561T3 (pt) |
FI (1) | FI3402821T3 (pt) |
HU (1) | HUE064205T2 (pt) |
IL (1) | IL260402B2 (pt) |
PL (1) | PL3402821T3 (pt) |
PT (1) | PT3402821T (pt) |
RU (1) | RU2762704C2 (pt) |
WO (1) | WO2017121905A1 (pt) |
ZA (1) | ZA201804601B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2794658T1 (sl) * | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
CN112351820A (zh) * | 2018-06-21 | 2021-02-09 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
CN114349867B (zh) * | 2020-10-14 | 2024-05-28 | 广东菲鹏制药股份有限公司 | 融合蛋白及其应用 |
AU2021392655A1 (en) * | 2020-12-01 | 2023-06-22 | The Johns Hopkins University | Methods and materials for treating t cell cancers |
CN112480260B (zh) * | 2020-12-09 | 2022-03-08 | 福州迈新生物技术开发有限公司 | 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用 |
EP4284838A2 (en) * | 2021-01-28 | 2023-12-06 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
JP2024517701A (ja) | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 組換え生産タンパク質の低分子量種を低減させる方法 |
WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
TW202405015A (zh) * | 2022-04-11 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合psma和cd28的抗原結合分子及其醫藥用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP2155788B1 (en) | 2007-04-03 | 2012-06-27 | Micromet AG | Cross-species-specific bispecific binders |
PL2155783T5 (pl) | 2007-04-03 | 2023-03-13 | Amgen Research (Munich) Gmbh | Swoista międzygatunkowo domena wiążąca CD3epsilon |
DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
EP2373622A2 (en) * | 2008-12-05 | 2011-10-12 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
SI2794658T1 (sl) | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
CA2917886A1 (en) * | 2013-07-12 | 2015-01-15 | Zymeworks Inc. | Bispecific cd3 and cd19 antigen binding constructs |
ES2683268T3 (es) * | 2013-07-25 | 2018-09-25 | Cytomx Therapeutics, Inc. | Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos |
US20170089885A1 (en) * | 2014-03-18 | 2017-03-30 | Aptevo Research And Development Llc | Cell line-based redirected t-cell cytotoxicity assay |
WO2015158868A2 (en) | 2014-04-16 | 2015-10-22 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
-
2016
- 2016-01-14 EP EP16151281.9A patent/EP3192810A1/en not_active Withdrawn
-
2017
- 2017-01-16 BR BR112018014215A patent/BR112018014215A2/pt unknown
- 2017-01-16 RU RU2018128414A patent/RU2762704C2/ru active
- 2017-01-16 CA CA3199697A patent/CA3199697A1/en active Pending
- 2017-01-16 JP JP2018556006A patent/JP6893939B2/ja active Active
- 2017-01-16 EP EP20162696.7A patent/EP3693396A3/en active Pending
- 2017-01-16 PT PT177012903T patent/PT3402821T/pt unknown
- 2017-01-16 FI FIEP17701290.3T patent/FI3402821T3/fi active
- 2017-01-16 WO PCT/EP2017/050834 patent/WO2017121905A1/en active Application Filing
- 2017-01-16 HU HUE17701290A patent/HUE064205T2/hu unknown
- 2017-01-16 DK DK17701290.3T patent/DK3402821T3/da active
- 2017-01-16 EP EP17701290.3A patent/EP3402821B1/en active Active
- 2017-01-16 US US16/069,656 patent/US11612646B2/en active Active
- 2017-01-16 CN CN201780014034.8A patent/CN108699157B/zh active Active
- 2017-01-16 IL IL260402A patent/IL260402B2/en unknown
- 2017-01-16 AU AU2017207947A patent/AU2017207947B9/en active Active
- 2017-01-16 ES ES17701290T patent/ES2963561T3/es active Active
- 2017-01-16 CA CA3011098A patent/CA3011098A1/en active Pending
- 2017-01-16 PL PL17701290.3T patent/PL3402821T3/pl unknown
-
2018
- 2018-07-10 ZA ZA2018/04601A patent/ZA201804601B/en unknown
-
2022
- 2022-09-22 US US17/934,232 patent/US20230132249A1/en active Pending
-
2023
- 2023-05-16 AU AU2023203041A patent/AU2023203041A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017207947B9 (en) | 2023-09-21 |
IL260402B1 (en) | 2023-08-01 |
IL260402B2 (en) | 2023-12-01 |
FI3402821T3 (fi) | 2023-10-26 |
AU2017207947A1 (en) | 2018-07-26 |
RU2762704C2 (ru) | 2021-12-22 |
AU2023203041A1 (en) | 2023-06-08 |
EP3693396A3 (en) | 2020-10-14 |
EP3192810A1 (en) | 2017-07-19 |
ES2963561T3 (es) | 2024-03-27 |
RU2018128414A3 (pt) | 2020-10-20 |
JP6893939B2 (ja) | 2021-06-23 |
EP3402821B1 (en) | 2023-08-23 |
EP3402821A1 (en) | 2018-11-21 |
CA3011098A1 (en) | 2017-07-20 |
US11612646B2 (en) | 2023-03-28 |
US20230132249A1 (en) | 2023-04-27 |
PT3402821T (pt) | 2023-09-26 |
CN108699157B (zh) | 2022-02-01 |
JP2019505589A (ja) | 2019-02-28 |
CA3199697A1 (en) | 2017-07-20 |
US20190022205A1 (en) | 2019-01-24 |
IL260402A (pt) | 2018-08-30 |
PL3402821T3 (pl) | 2024-03-04 |
EP3693396A2 (en) | 2020-08-12 |
AU2017207947B2 (en) | 2023-09-07 |
RU2018128414A (ru) | 2020-02-14 |
DK3402821T3 (da) | 2023-11-06 |
HUE064205T2 (hu) | 2024-02-28 |
ZA201804601B (en) | 2019-04-24 |
WO2017121905A1 (en) | 2017-07-20 |
CN108699157A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018014215A2 (pt) | anticorpo de ligação ao psma e usos do mesmo | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
BR112018003339A8 (pt) | Anticorpos antimesotelina completamente humanos e células imunoefetoras que direcionam mesotelina | |
BR112018068678A2 (pt) | anticorpos anti-mica | |
AU359077S (en) | A cover of a blending system | |
BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
TWD170353S (zh) | 項鍊 | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
TWD173639S (zh) | 針盤 | |
BR112016027222A2 (pt) | anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer | |
AU201616137S (en) | Reagent plate | |
BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
EP3420357C0 (en) | IMMUNOLOGICAL ASSAY FOR DIAGNOSIS OF VIRAL INFECTION WITH ZIKA VIRUS | |
MX2016012471A (es) | Recipiente con represa plegada. | |
MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
MX2018010491A (es) | Proceso para la preparacion de un conjugado anticuerpo-rifamicina. | |
CL2019002323A1 (es) | Anticuerpo dirigido a il-13ra2 y su uso. | |
MX2019011349A (es) | Explante de tejido macro, métodos y del mismo. | |
WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies | |
CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
WO2015113055A3 (en) | Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ade) of infection | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
GB201813137D0 (en) | Cancer treatment with an antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024001133-6 PROTOCOLO 870240005066 EM 19/01/2024 12:57. |